Telehealth prescribing rules: state-by-state changes in 2026
Eight states tightened controlled-substance telehealth in early 2026 after the federal DEA rule expired. Here's what changed and where you can still get care online.
By WeighedHealth Editorial
2 min readUpdated
The federal flexibilities that allowed telehealth controlled-substance prescribing without an in-person visit (in place since 2020 COVID emergency) finally expired in November 2025. The DEA's permanent rule replaced it with a narrower carve-out: 30-day controlled-substance prescriptions OK telehealth-only, anything beyond requires one in-person visit within the prior 6 months.
States that tightened further
Eight states added rules on top of the federal baseline. California, New York, Massachusetts, and Washington require synchronous (video, not async) visits for new mental-health controlled-substance prescribing. Texas, Florida, Tennessee, and Georgia preserved looser async rules in line with the federal floor.
WeighedHealth's offer pages reflect each state's eligibility per program. The state-availability matrix updates monthly. If you're in a state that tightened, expect some brands to drop you out of their async funnel during intake — that's the state law, not the brand being difficult.
What's unaffected
Non-controlled prescribing — GLP-1s, finasteride, sildenafil, tretinoin, antibiotics, SSRIs — remains async-friendly across all 50 states. The new rules apply only to controlled substances (Schedule II-V: stimulants for ADHD, benzodiazepines, opioids, ketamine).
If your treatment is on the non-controlled side, nothing changed for you. If you take Adderall, Vyvanse, Xanax, Klonopin, or Suboxone via telehealth, expect more friction — either an in-person establishing visit, or a switch to a non-controlled alternative.
Related reads
Modern Fertility AMH testing: what 95th vs 5th percentile means (2026)
An AMH result at the 5th percentile doesn't mean infertility, and a result at the 95th percentile doesn't mean abundant fertility. Here's what the test actually measures and what high or low values predict.
Ozempic for PCOS: off-label evidence 2026 review
Semaglutide is being prescribed off-label for PCOS more often each year. Here's what the published trials actually show on weight, ovulation, insulin resistance, and androgen levels — and what they don't.
Wegovy prior authorization: the step-by-step approval playbook (2026)
Wegovy denials usually come from incomplete documentation, not clinical ineligibility. Here's the exact step-by-step process that gets approval on the first submission, plus what to do when denied.